We develop endothelial cell-targeted LNPs through affinity ligand display, charge-engineered lipid design, and hepatic detargeting, providing end-to-end support from lipid synthesis and ligand conjugation to formulation, characterization, and in vivo endothelial delivery evaluation.
Endothelial cell-targeted LNPs are engineered to deliver nucleic acids and other payloads to the vascular endothelium—the single-cell lining of blood vessels that governs vascular barrier function, inflammation, remodeling, and angiogenesis. Unlike conventional LNPs that are captured almost entirely by the liver through ApoE adsorption and LDL receptor–mediated uptake, endothelium-directed formulations use surface-displayed antibodies, antibody fragments, peptides, or aptamers against endothelial markers such as PECAM-1 (CD31), ICAM-1 (CD54), VCAM-1 (CD106), and ACE, or exploit charge-based tropism through cationic and SORT lipid strategies to redirect biodistribution toward lung, cardiac, splenic, brain, or tumor vasculature.
BOC Sciences provides integrated targeted LNP development for endothelial delivery, covering ionizable and cationic lipid design, targeting ligand synthesis, multivalent surface conjugation, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing payloads, with each design built around the target organ's endothelium, the intended cell population, and the delivery route.
Endothelial Cell-Targeted Lipid Nanoparticle IllustrationOur development services integrate lipid chemistry, ligand engineering, nanoparticle formulation, and biological evaluation to address the specific barriers of endothelial delivery: hepatic sequestration, ligand masking by the protein corona, inefficient internalization of monovalent ligands, and post-uptake endosomal trapping. Projects can start with an existing LNP formulation, a candidate endothelial ligand, or a defined vascular-delivery objective, and the development scope is customized according to payload properties, target organ, and administration route.
We investigate how ionizable and cationic lipid structures, helper lipid balance, and PEG-lipid architecture influence endothelial interactions, circulation persistence, and tissue distribution.
We develop ligand-functionalized LNPs that recognize endothelial surface markers, with ligand identity, valency, orientation, and density optimized together—because endothelial cells internalize different targets with very different efficiencies.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy matched to the intended vascular bed and application.
We evaluate candidate LNPs across particle, cell, and tissue levels to confirm that endothelial targeting translates into functional payload delivery—not just binding.
Endothelial cell-targeted LNPs can be developed through affinity ligand display, charge-engineered lipid compositions, intrinsic lipid architecture, and hepatic detargeting. BOC Sciences supports ligand synthesis, lipid design and production, LNP formulation, and delivery evaluation. The following strategies can be applied alone or in combination.
Affinity targeting redirects systemically administered LNPs to endothelial cells by displaying recognition components against accessible vascular markers such as PECAM-1, ICAM-1, VCAM-1, ACE, E-selectin, or PV1. Anti-PECAM-1–conjugated LNPs, for example, have been reported to redirect mRNA delivery to the pulmonary endothelium at approximately 100% injected dose per gram of lung tissue, and replacing full antibodies with Fab fragments has further improved expression magnitude, duration, and organ-type specificity. BOC Sciences supports ligand selection, conjugation chemistry, and surface-density optimization.
Research reference: αPECAM-Fab–conjugated DNA-LNPs redirecting expression to pulmonary endothelial cells (Advanced Science, 2026).
Introducing permanently cationic lipids or SORT components shifts LNP biodistribution toward the lung and other vascular beds, driven partly by electrostatic interactions with anionic proteoglycans on the endothelial surface. Cationic LNPs carrying Tie2-agonist mRNA (COMP-Ang1) have been shown to deliver almost exclusively to lung endothelial cells while bypassing the liver, restoring vascular barrier function in vascular leakage models. Because charge-based tropism introduces its own formulation trade-offs, this strategy is best paired with systematic charge titration and matched controls.
Research reference: Cationic LNP-formulated Tie2-agonist mRNA delivered almost exclusively to lung endothelium (Molecular Therapy, 2023).
Endothelium-tropic behavior can also be achieved without surface ligands by engineering the intrinsic structures of ionizable lipids and PEG-lipids. High-throughput barcoded screening of chemically diverse LNP libraries has identified ionizable-lipid compositions—such as the 7C2 and 7C3 LNPs—that deliver functional mRNA and even Cas9 mRNA/sgRNA to endothelial cells in vivo. Similarly, PEG-lipid anchor length, branching, and molar fraction modulate surface properties that determine vascular-wall interactions and circulation behavior.
Research reference: FIND screen of >250 LNPs identifying endothelium-tropic 7C2/7C3 LNPs for endothelial gene editing (PNAS, 2018).
Even well-designed targeting ligands can fail if the LNP is intercepted by the liver first or if serum protein adsorption masks the ligand layer. Hepatic detargeting and corona engineering address this competitive loss of payload: precoating or lipid-design strategies that reduce ApoE-mediated hepatocyte uptake have been shown to substantially increase target-to-liver expression ratios for antibody-conjugated LNPs without compromising endothelial delivery.
Research reference: ApoE-detargeting combined with CD54 (ICAM-1) antibody conjugation markedly increased lung-to-liver delivery ratios (bioRxiv, 2026).
Share your payload, target organ, and endothelial cell type. BOC Sciences can help evaluate feasible design options, synthesize the relevant components, and develop a comparative formulation strategy.
BOC Sciences develops endothelial cell-targeted LNPs for the payload classes most frequently used in vascular and endothelium-focused research. Each payload requires a matched loading strategy, particle design, and functional readout, and we help connect endothelial-targeting design with payload-specific formulation requirements.
| Payload Type | Supported Uses & Endothelial-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Endothelial-Targeted LNP for mRNA | Designed for transient expression of endothelial-active proteins such as Tie2 agonists, VEGF-A, VEGF-C, and other vascular-protective or pro-angiogenic factors. Development focuses on mRNA integrity, lung or target-organ endothelium expression, and endothelium-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Endothelial-Targeted LNP for siRNA | Suitable for silencing vascular-signaling targets such as TGF-β pathway components and adhesion-molecule regulators in endothelial cells, with knockdown confirmed in CD31-positive cell populations. Development evaluates silencing selectivity against hepatocyte uptake, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Endothelial-Targeted LNP for miRNA | Applicable to endothelial miRNA biology, including miR-126- and miR-146-class modulators of vascular inflammation and barrier function. Development covers strand integrity, loading stability during ligand conjugation, and functional readouts in endothelial models, supported by our lipid nanoparticles for miRNA delivery services. | Inquiry |
| Endothelial-Targeted LNP for Cas9 mRNA and sgRNA | Designed for endothelial gene-editing research, where transient Cas9 expression and repeat-dosing capability are key advantages of LNP delivery. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in endothelial cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Endothelial-Targeted LNP for Plasmid DNA | Applicable when longer-duration endothelial expression is needed for chronic vascular disease models. Development focuses on pDNA loading, nuclear delivery efficiency, cytosolic DNA-sensor–related inflammatory considerations, and sustained endothelial expression, supported by our lipid nanoparticles for pDNA delivery platform. | Inquiry |
| Endothelial-Targeted LNP for circRNA and saRNA | Designed for payloads requiring strong protection and sustained expression in endothelial cells, such as prolonged production of vascular growth factors. Development considers payload integrity, encapsulation behavior, and expression duration in endothelial models, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| Endothelial-Targeted LNP for Protein and Peptide | Applicable to vasoactive proteins, thrombomodulin-class enzymes, and peptide payloads intended for endothelium-focused research. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Endothelial-Targeted LNP for Small Molecule | Designed for vasoactive, anti-inflammatory, and anti-proliferative small molecules studied in vascular remodeling and tumor-vasculature research. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release behavior at the target vasculature, supported by lipid nanoparticles for small molecule delivery. | Inquiry |
| Endothelial-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map endothelium-associated uptake, distinguish vascular from parenchymal localization, and quantify organ-level distribution trends, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| Endothelial-Targeted LNP for Custom and Co-Delivery | Developed for combination payloads—such as nucleic acids co-loaded with anti-inflammatory lipid components—or early feasibility studies. We evaluate payload compatibility, loading sequence, targeting modification route, and delivery performance in the agreed endothelial models, supported by our lipid nanoparticles for co-delivery services. | Inquiry |
Tell us your payload, target vasculature, and delivery goal, and BOC Sciences will propose an endothelial-targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate endothelial ligand, or only a vascular-delivery objective. We organize the work into four practical stages and refine the plan as formulation and biological evidence accumulates.

We review the payload class, target organ (lung, heart, brain, spleen, or tumor vasculature), intended endothelial population—continuous, fenestrated, or sinusoidal; healthy or inflamed—baseline formulation if available, and desired biological readouts. Whether the endothelium is quiescent or activated determines which surface markers (constitutive PECAM-1 versus inducible VCAM-1 or E-selectin) are appropriate, and these inputs define the screening plan.

We propose candidate ionizable or cationic lipid compositions, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer—affinity ligand display, charge-based tropism, or intrinsic lipid selectivity. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted and hepatic-detargeted control LNPs.

Candidates are prepared under controlled mixing conditions, ligand conjugation is performed and verified, and particles are compared for size, PDI, zeta potential, ligand density, and payload retention. During LNP process optimization, we adjust composition, ligand input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds—typically including post-conjugation size increase within agreed limits and PDI below agreed cutoffs.

Selected candidates are evaluated in endothelial cell models under static and flow conditions using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression or gene knockdown. Combined nanoparticle in vivo distribution analysis then quantifies target-organ endothelial delivery against hepatic and splenic accumulation. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
An endothelial-targeted LNP may be well characterized chemically yet still deliver mostly to the liver, or bind endothelial cells without producing measurable payload expression. We investigate formulation and biological factors together and use matched comparison studies to identify the step limiting performance.
✔ Hepatic Accumulation Diverting LNPs Away from Endothelial Targets
ApoE adsorption and LDL receptor–mediated uptake draw conventional LNPs into the liver before they ever reach the target vasculature. We compare ionizable and cationic lipid structures, PEG-lipid densities, and detargeting modifications to shift biodistribution, and we quantify the target-endothelium-to-liver delivery ratio for every candidate rather than relying on total expression data.
✔ Ligand-Displayed LNPs That Bind Endothelium Without Functional Uptake (Multivalency and Receptor Selection)
Endothelial cells internalize different targets with very different efficiencies: monovalent ligands may adhere to the endothelial surface without being internalized, while certain markers require multivalent engagement before uptake occurs. We compare ligand formats—full antibody, Fab, peptide, aptamer—alongside valency and surface density, and we pair uptake measurements with functional readouts so that binding without internalization is detected early rather than after animal work.
✔ Protein Corona Masking LNP Surface Ligands and Compromising Particle Stability
Serum proteins such as apolipoproteins, albumin, and vitronectin adsorb onto LNP surfaces within minutes of administration, altering biodistribution and physically masking targeting ligands. We evaluate particle behavior in serum-containing systems, measure ligand accessibility alongside corona-related changes, and adjust PEG architecture, ligand spacer length, and surface composition so the targeting layer survives circulation.
✔ Cationic-Lipid LNP Trade-offs Between Endothelial Tropism and Vascular Compatibility
Permanently cationic lipids can drive strong lung-endothelium tropism, but higher charge content also changes aggregation behavior and blood-interaction profiles. We titrate cationic content systematically, compare charge-reversible and hybrid ionizable designs, and track how each charge level affects particle attributes, serum stability, and cell-type selectivity, so the tropism benefit is achieved at the lowest workable charge content.
Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.
Endothelial cell-targeted LNPs create opportunities for nucleic acid and drug delivery across vascular and perfusion-linked diseases, from lung barrier injury to tumor angiogenesis. BOC Sciences supports customized LNP development for these applications, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.
Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate endothelial cell-targeted LNPs tailored to your project.
We connect ionizable and cationic lipid structure, helper lipid balance, and PEG architecture to endothelial biodistribution outcomes, helping teams move beyond liver-tropic default formulations with a defined, data-supported design logic.

Our conjugation workflows cover antibodies, Fab fragments, homing peptides, and aptamers with controlled valency, spacer length, and surface density—addressing the well-documented gap between endothelial surface binding and functional internalization.
Lipid components are designed and synthesized in-house, enabling rapid iteration between headgroup, tail, linker, and anchor structures and the corresponding particle performance, without dependency on fixed commercial platforms.
Particle profiling, endothelial-cell uptake and functional readouts under static and flow conditions, and in vivo distribution studies are combined in one program, so formulation changes can be interpreted against both cellular and tissue-level delivery data.
Every targeting design is evaluated against matched non-targeted and detargeted controls, so conclusions about ligand contribution, charge effect, and liver background are quantitative and directly actionable for the next iteration.
Systemically administered conventional LNPs are coated by apolipoprotein E in blood, which redirects them to hepatocytes through LDL receptor–mediated uptake, so the majority of the dose is cleared by the liver before vascular endothelium is exposed. Because hepatic sinusoids offer slow blood flow and fenestrated barriers, liver sequestration is a competitive, physiologically favored route. Overcoming it requires either surface ligands that engage endothelial markers such as PECAM-1, ICAM-1, or VCAM-1, charge-engineered compositions that favor pulmonary endothelium, or detargeting strategies that suppress ApoE-mediated hepatic capture while preserving endothelial delivery.
Increasing the cationic lipid fraction shifts LNP surface charge positive, promoting interaction with negatively charged proteoglycans that are enriched on pulmonary endothelial surfaces. SORT-based designs pair such ionizable/cationic components with a selected SORT molecule to retarget RNA payloads to lung vasculature. Reported cationic formulations have delivered Tie2-agonist mRNA almost exclusively to lung endothelium in animal studies. The trade-off is vascular compatibility: excessive positive charge raises complement interaction and procoagulant risk, so cationic fraction must be titrated against serum stability and hemocompatibility rather than maximized.
Commonly used ligands include antibodies or Fab fragments against PECAM-1 (CD31), ICAM-1 (CD54), VCAM-1, and ACE; peptides such as cyclic RGD that recognize αvβ3-integrin on angiogenic endothelium; and nucleic acid aptamers selected against endothelial surface proteins. Ligand choice determines both organ tropism and uptake efficiency, because different endothelial receptors internalize at very different rates. BOC Sciences supports ligand synthesis, selection, and conjugation chemistry—including antibody-, peptide-, and aptamer-displayed LNPs—and optimizes ligand density and orientation so that binding converts into functional cellular uptake rather than surface attachment.
Binding is not uptake. Many endothelial receptors, such as ICAM-1, internalize efficiently only when engaged by multivalent, cluster-forming ligands, whereas monovalent antibody display often leaves particles stuck at the cell surface. Receptor identity matters as well: PECAM-1–mediated uptake differs markedly from ICAM-1– or ACE-mediated routes in kinetics and intracellular destination. At BOC Sciences, we systematically compare monovalent versus multivalent display, screen ligand density, and evaluate internalization in primary endothelial cells, so candidates are selected on functional delivery rather than binding signals alone.
Organ-level fluorescence is not enough, because lung or liver signal can originate from epithelial cells, macrophages, or hepatocytes rather than endothelium. Credible verification combines quantitative biodistribution with cell-type resolution: flow cytometry or imaging of marker-defined cell populations (for example CD31⁺ or CD45⁻ compartments), barcoded LNP libraries that rank delivery per cell type, and functional readouts such as reporter expression, knockdown depth, or editing efficiency in sorted endothelial cells. BOC Sciences provides matched non-targeted and hepatic-detargeted controls alongside these assays so that endothelial selectivity is demonstrated, not assumed.